FDA Expands Dysport Approval for Treatment of Lower Limb Spasticity in Adults
News
The U.S. Food and Drug Administration (FDA) has expanded approval of Dysport (abobotulinumtoxinA) for the treatment of lower limb spasticity in adults based on its supplemental Biologics License Application (sBLA), according ... Read more